AYTU — AYTU BIOPHARMA, INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1385818 ·
Last close
$2.18
Market Cap
$23.40M
52W High
$2.80
52W Low
$1.98
ADV30
47,102
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 12,411,000 | 7,599,000 | -4,064,000 | -5,618,000 | 111,689,000 | 26,715,000 | 76,546,000 |
| Dec 2025 | 15,165,000 | 9,624,000 | -1,970,000 | -10,584,000 | 122,000,000 | 30,025,000 | 107,799,000 |
| Sep 2025 | 13,888,000 | 9,186,000 | -1,504,000 | 1,965,000 | 124,988,000 | 32,630,000 | 101,817,000 |
| Jun 2025 | 15,135,000 | 10,254,000 | 640,000 | -19,818,000 | 124,177,000 | 30,952,000 | 105,211,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-595,000
Investing CF
$-3,103,000
Financing CF
$13,325,000
CapEx
$-3,228,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.18
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-342,154,000
Inventory
$8,656,000
Receivables
$30,923,000
ST Investments
—
EBIT TTM
$-21,538,000
Pretax Income TTM
$-24,244,000
Interest Exp TTM
$2,706,000
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$56,599,000
EBITDA
$-2,625,000
Free Cash Flow
$-1,073,500
Enterprise Value
$18,607,726
Total Cash
$26,715,000
Total Debt
$21,817,000
Shares Out
10,733,208
Trailing EPS
$-4.64
Book Value
$3.27
ROE
-97.4%
ROA
-3.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Jun 2025 | 66,382,000 | 2,537,000 | -13,562,000 | 124,177,000 | 105,211,000 | — | -1,937,000 |
| Jun 2024 | 65,183,000 | 565,000 | -15,844,000 | 118,095,000 | 90,379,000 | — | -1,388,000 |
| Jun 2023 | 107,399,000 | -12,329,000 | -17,051,000 | 136,463,000 | 97,106,000 | — | -5,129,000 |
| Jun 2022 | 96,669,000 | -36,103,000 | -108,779,000 | 137,623,000 | 93,315,000 | — | -28,823,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.05
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TRAW | Traws Pharma, Inc. | $23.94M | $1.58 | — |
| KTTA | Pasithea Therapeutics Corp. | $22.73M | $0.68 | — |
| VYNE | VYNE Therapeutics Inc. | $22.66M | $0.68 | — |
| MRKR | Marker Therapeutics, Inc. | $24.18M | $1.45 | — |
| HOWL | Werewolf Therapeutics, Inc. | $22.51M | $0.46 | — |
News headlines (Yahoo Finance, 1h cache)
Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
2026-05-18 20:05 · Yahoo
Aytu BioPharma, Inc. Q3 2026 Earnings Call Summary
2026-05-14 12:30 · Yahoo
Aytu BioPharma Inc (AYTU) Q3 2026 Earnings Call Highlights: Strong Exua Adoption Amid Revenue ...
2026-05-14 05:02 · Yahoo
Aytu (AYTU) Q3 2026 Earnings Transcript
2026-05-13 21:54 · Yahoo
Full Transcript: Aytu BioPharma Q3 2026 Earnings Call
2026-05-13 21:39 · Yahoo
Aytu BioPharma, Inc. (AYTU) Reports Q3 Loss, Tops Revenue Estimates
2026-05-13 21:35 · Yahoo
Aytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial Results
2026-05-13 20:05 · Yahoo
Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates
2026-05-12 12:25 · Yahoo
Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue Estimates
2026-05-07 23:05 · Yahoo
Aytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026
2026-05-06 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.